Giesel FL, et al. - After radical prostatectomy, researchers studied the diagnostic effectiveness of ¹⁸F-prostate-specific membrane antigen (PSMA)-1007 for biochemical recurrence (BCR). In a retrospective analysis, 251 patients with BCR were assessed following radical prostatectomy in one of three academic centers. Previous exposure to first-line ADT was permitted, but patients with second-line androgen deprivation therapy or chemotherapy were excluded. Of the 251 patients, on ¹⁸F-PSMA-1007 PET/CT, 204 (81.3%) had evidence of recurrence. According to findings, ¹⁸F-PSMA-1007 PET/CT provides high detection rates for BCR following radical prostatectomy similar to or better than those published for ⁶⁸Ga-labeled PSMA ligands.